The anti-obesity medication stock is way up, and there could be more fuel in the tank.
Growth stocks such as Viking Therapeutics, Cresco Labs, and Alphatec Holdings continue to trade at a significant discount to analysts' consensus price target estimates.
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
This midcap biotech could see huge success ahead -- or disappointment.
Tom Lee of Fundstrat Global Advisors thinks the small-cap Russell 2000 could climb 50% by the end of 2024.
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
These two pharma stocks have followed distinct paths of late. Which is the better investment?
This Vanguard growth fund is home to some of the world's most innovative companies.
There's no guarantee these stocks will double by 2030, but their growth prospects look great.